Lupin Receives 'Hold' Rating from MarketsMOJO Despite Strong Financial Performance

Pharmaceutical giant Lupin . has recently received a 'Hold' rating from MarketsMOJO, a leading financial analysis platform. This downgrade comes as the company's stock has been on a mildly bullish trend, with technical factors such as MACD and KST also showing bullish signals.
One of the main reasons for this downgrade is the company's high institutional holdings, which stand at 46.06%. This indicates that these investors have better resources and capabilities to analyze the fundamentals of the company compared to retail investors.

However, Lupin . has shown strong financial performance in recent years, with a growth in net profit of 118.77% and positive results for the last 7 consecutive quarters. The company also has a strong ability to service debt, with a low Debt to EBITDA ratio of 1.27 times.

On the other hand, Lupin . has a poor long-term growth rate, with operating profit growing at an annual rate of -13.89% over the last 5 years. This has resulted in a relatively expensive valuation for the company, with a price to book value of 7.

Despite this, Lupin . has outperformed the BSE 500 index in the last 3 years, 1 year, and 3 months, and has generated a return of 86.94% in the last year. However, its profits have only risen by 133%, resulting in a low PEG ratio of 0.3.

In conclusion, while Lupin . has shown strong financial performance and a bullish trend in the stock market, the high institutional holdings and expensive valuation have led to a 'Hold' rating from MarketsMOJO. Investors should carefully consider these factors before making any investment decisions.